Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
CORTES, JORGE E
One or more keywords matched the following items that are connected to CORTES, JORGE E
Item TypeName
Academic Article Congestive heart failure is a rare event in patients receiving imatinib therapy.
Academic Article Imatinib effect on growth and signal transduction in polycythemia vera.
Academic Article Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Concept Piperazines
Academic Article Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
Academic Article AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Academic Article AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
Academic Article A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Academic Article Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
Academic Article Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Academic Article Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Academic Article New targeted approaches in chronic myeloid leukemia.
Academic Article Overcoming drug resistance in chronic myeloid leukemia.
Academic Article New strategies in chronic myeloid leukemia.
Academic Article Chronic myeloid leukemia: diagnosis and treatment.
Academic Article Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Academic Article New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Academic Article Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Academic Article Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Academic Article Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Academic Article Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Academic Article Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Academic Article Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Academic Article Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Academic Article Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
Academic Article Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.
Academic Article Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Academic Article Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
Academic Article Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Academic Article Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Academic Article Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
Academic Article Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Academic Article Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.
Academic Article Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Academic Article Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Academic Article Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
Academic Article Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.
Academic Article Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
Academic Article Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Academic Article Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
Academic Article Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
Academic Article Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
Academic Article Chronic myeloid leukemia: the race is yet to be won.
Academic Article Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
Academic Article Nilotinib-associated vascular events.
Academic Article Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Academic Article SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.
Academic Article Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Academic Article Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Academic Article Chronic myelogenous leukemia.
Academic Article Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Academic Article Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Academic Article Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
Academic Article Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Academic Article Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Academic Article Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Academic Article The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Academic Article Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Academic Article Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Academic Article Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Academic Article Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group.
Academic Article Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
Academic Article High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Academic Article Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Academic Article Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Academic Article Natural history and staging of chronic myelogenous leukemia.
Academic Article Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Academic Article Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Academic Article Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Academic Article Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Academic Article Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Academic Article Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Academic Article Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
Academic Article Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Academic Article The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Academic Article A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Academic Article Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
Academic Article Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
Academic Article The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Academic Article Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Academic Article Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Academic Article BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Academic Article Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Academic Article Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha.
Academic Article Management of patients with resistant or refractory chronic myelogenous leukemia.
Academic Article Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Academic Article The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Academic Article Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
Academic Article Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Academic Article Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
Academic Article Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Academic Article Treatment selection after imatinib resistance in chronic myeloid leukemia.
Academic Article Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Academic Article Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Academic Article Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
Academic Article Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
Academic Article Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Academic Article Chronic myeloid leukemia: where do we go now?
Academic Article Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Academic Article Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Academic Article Tyrosine kinase inhibitors: the first decade.
Academic Article Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.
Academic Article Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Academic Article Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Academic Article The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
Academic Article Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
Academic Article Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Academic Article Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
Academic Article Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Academic Article Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
Academic Article Chronic myeloid leukemia: mechanisms of resistance and treatment.
Academic Article Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Academic Article Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Academic Article EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
Academic Article Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Academic Article Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
Academic Article Bosutinib in the treatment of chronic myelogenous leukemia.
Academic Article Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
Academic Article Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
Academic Article Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.
Academic Article Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
Academic Article Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Academic Article Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Academic Article Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Academic Article Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Academic Article Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Academic Article Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Academic Article Imatinib mesylate causes hypopigmentation in the skin.
Academic Article Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Academic Article Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
Academic Article Investigational strategies in chronic myelogenous leukemia.
Academic Article Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Academic Article Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Academic Article Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Academic Article Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Academic Article The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Academic Article Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Academic Article Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Academic Article Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Academic Article Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Academic Article Kinase inhibitors in chronic myelogenous leukemia.
Academic Article Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Academic Article MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Academic Article Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Academic Article In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Academic Article Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Academic Article Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Academic Article Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Academic Article Important therapeutic targets in chronic myelogenous leukemia.
Academic Article Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Academic Article Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Academic Article The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Academic Article Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Academic Article The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Academic Article FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Academic Article Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Academic Article Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Academic Article Nilotinib therapy in chronic myelogenous leukemia.
Academic Article Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Academic Article An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
Academic Article The effects of imatinib on pregnancy outcome.
Academic Article Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
Academic Article Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Academic Article Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Academic Article Imatinib therapy for chronic myeloid leukemia: where do we go now?
Academic Article Pregnancy in a patient with hypereosinophilic syndrome.
Academic Article Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia.
Academic Article Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT.
Academic Article BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
Academic Article Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Academic Article Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
Academic Article Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Academic Article Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Academic Article Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.
Academic Article Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Academic Article Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
Academic Article Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Academic Article Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
Academic Article Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Academic Article Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.
Academic Article Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Academic Article Imatinib and beyond--exploring the full potential of targeted therapy for CML.
Academic Article Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature.
Academic Article High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Academic Article The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Academic Article Standard management of patients with chronic myeloid leukemia.
Academic Article Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Academic Article Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Academic Article Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Academic Article Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET).
Academic Article Towards a cure for chronic myeloid leukemia: are we there yet?
Academic Article Third-generation tyrosine kinase inhibitors and beyond.
Academic Article Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
Academic Article Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Academic Article Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Academic Article Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
Academic Article Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Academic Article Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.
Academic Article Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Academic Article Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Academic Article Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Academic Article Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Academic Article Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
Academic Article Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Academic Article Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia.
Academic Article Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
Academic Article Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Academic Article European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Academic Article KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Academic Article Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
Academic Article Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
Academic Article Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia.
Academic Article Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Academic Article Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
Academic Article Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Academic Article The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Academic Article Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Academic Article Discontinuation of imatinib therapy after achieving a molecular response.
Academic Article Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Academic Article Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Academic Article Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Academic Article Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Academic Article Current and emerging treatment options in chronic myeloid leukemia.
Academic Article Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
Academic Article Farnesyl transferase inhibitor resistance probed by target mutagenesis.
Academic Article Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.
Academic Article Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Academic Article Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Academic Article Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Academic Article First-line therapy for chronic myeloid leukemia: Past, present, and future.
Academic Article Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Academic Article Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Academic Article Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Academic Article Optimizing first-line therapy for patients with chronic myeloid leukemia.
Academic Article New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.
Academic Article Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Academic Article Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Academic Article Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
Academic Article Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.
Academic Article Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Academic Article The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm.
Academic Article Molecular resistance: an early indicator for treatment change?
Academic Article Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
Academic Article Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
Academic Article CML: the good, the better, and the difficult choices.
Academic Article The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
Academic Article Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Academic Article HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
Academic Article Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Academic Article Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
Academic Article Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Academic Article Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
Academic Article Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Academic Article Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Academic Article Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Academic Article Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.
Academic Article Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Academic Article New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Academic Article Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
Academic Article Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Academic Article Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Academic Article Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Academic Article Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Academic Article Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Academic Article Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
Academic Article Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Academic Article Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
Academic Article Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
Academic Article Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Academic Article Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Academic Article Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Academic Article Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
Academic Article Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.
Academic Article Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
Academic Article Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Search Criteria
  • Piperazines